Thus, future experiments using other PD-like synucleinopathy models, depicting no systemic toxicity and high lethality, such as overexpression of human wild-type or mutant α-synuclein using Adeno-Associated Virus (AAV) vectors [47–49] should be used to foster clinical translation of our data. Here, SNCA is linked to synucleinopathy.